首页 > 最新文献

Pneumologie最新文献

英文 中文
[Management of adult bronchiectasis - Consensus-based Guidelines for the German Respiratory Society (DGP) e. V. (AWMF registration number 020-030)]. [成人支气管扩张症的管理 - 德国呼吸学会 (DGP) e. V. 的共识指南(AWMF 注册号 020-030)]。(AWMF注册号020-030)]。
IF 1.7 Q4 RESPIRATORY SYSTEM Pub Date : 2024-11-01 Epub Date: 2024-11-08 DOI: 10.1055/a-2311-9450
Felix C Ringshausen, Ingo Baumann, Andrés de Roux, Sabine Dettmer, Roland Diel, Monika Eichinger, Santiago Ewig, Holger Flick, Leif Hanitsch, Thomas Hillmann, Rembert Koczulla, Michael Köhler, Assen Koitschev, Christian Kugler, Thomas Nüßlein, Sebastian R Ott, Isabell Pink, Mathias Pletz, Gernot Rohde, Ludwig Sedlacek, Hortense Slevogt, Urte Sommerwerck, Sivagurunathan Sutharsan, Sönke von Weihe, Tobias Welte, Michael Wilken, Jessica Rademacher, Pontus Mertsch

Bronchiectasis is an etiologically heterogeneous, chronic, and often progressive respiratory disease characterized by irreversible bronchial dilation. It is frequently associated with significant symptom burden, multiple complications, and reduced quality of life. For several years, there has been a marked global increase in the prevalence of bronchiectasis, which is linked to a substantial economic burden on healthcare systems. This consensus-based guideline is the first German-language guideline addressing the management of bronchiectasis in adults. The guideline emphasizes the importance of thoracic imaging using CT for diagnosis and differentiation of bronchiectasis and highlights the significance of etiology in determining treatment approaches. Both non-drug and drug treatments are comprehensively covered. Non-pharmacological measures include smoking cessation, physiotherapy, physical training, rehabilitation, non-invasive ventilation, thoracic surgery, and lung transplantation. Pharmacological treatments focus on the long-term use of mucolytics, bronchodilators, anti-inflammatory medications, and antibiotics. Additionally, the guideline covers the challenges and strategies for managing upper airway involvement, comorbidities, and exacerbations, as well as socio-medical aspects and disability rights. The importance of patient education and self-management is also emphasized. Finally, the guideline addresses special life stages such as transition, family planning, pregnancy and parenthood, and palliative care. The aim is to ensure comprehensive, consensus-based, and patient-centered care, taking into account individual risks and needs.

支气管扩张症是一种病因复杂的慢性呼吸系统疾病,通常呈进行性发展,其特点是支气管不可逆性扩张。它常常伴有严重的症状负担、多种并发症和生活质量下降。几年来,支气管扩张症的发病率在全球范围内明显上升,给医疗系统带来了巨大的经济负担。这份基于共识的指南是第一份针对成人支气管扩张症治疗的德语指南。该指南强调了使用 CT 进行胸部成像对诊断和鉴别支气管扩张症的重要性,并强调了病因对确定治疗方法的重要意义。指南全面涵盖了非药物治疗和药物治疗。非药物治疗措施包括戒烟、物理治疗、体能训练、康复、无创通气、胸腔手术和肺移植。药物治疗的重点是长期使用粘液溶解剂、支气管扩张剂、抗炎药物和抗生素。此外,该指南还涉及管理上呼吸道受累、合并症和病情加重的挑战和策略,以及社会医疗方面和残疾人权利。指南还强调了患者教育和自我管理的重要性。最后,该指南还涉及特殊的生命阶段,如过渡、计划生育、怀孕和生育以及姑息治疗。其目的是确保提供全面、基于共识和以患者为中心的护理,同时考虑到个人风险和需求。
{"title":"[Management of adult bronchiectasis - Consensus-based Guidelines for the German Respiratory Society (DGP) e. V. (AWMF registration number 020-030)].","authors":"Felix C Ringshausen, Ingo Baumann, Andrés de Roux, Sabine Dettmer, Roland Diel, Monika Eichinger, Santiago Ewig, Holger Flick, Leif Hanitsch, Thomas Hillmann, Rembert Koczulla, Michael Köhler, Assen Koitschev, Christian Kugler, Thomas Nüßlein, Sebastian R Ott, Isabell Pink, Mathias Pletz, Gernot Rohde, Ludwig Sedlacek, Hortense Slevogt, Urte Sommerwerck, Sivagurunathan Sutharsan, Sönke von Weihe, Tobias Welte, Michael Wilken, Jessica Rademacher, Pontus Mertsch","doi":"10.1055/a-2311-9450","DOIUrl":"10.1055/a-2311-9450","url":null,"abstract":"<p><p>Bronchiectasis is an etiologically heterogeneous, chronic, and often progressive respiratory disease characterized by irreversible bronchial dilation. It is frequently associated with significant symptom burden, multiple complications, and reduced quality of life. For several years, there has been a marked global increase in the prevalence of bronchiectasis, which is linked to a substantial economic burden on healthcare systems. This consensus-based guideline is the first German-language guideline addressing the management of bronchiectasis in adults. The guideline emphasizes the importance of thoracic imaging using CT for diagnosis and differentiation of bronchiectasis and highlights the significance of etiology in determining treatment approaches. Both non-drug and drug treatments are comprehensively covered. Non-pharmacological measures include smoking cessation, physiotherapy, physical training, rehabilitation, non-invasive ventilation, thoracic surgery, and lung transplantation. Pharmacological treatments focus on the long-term use of mucolytics, bronchodilators, anti-inflammatory medications, and antibiotics. Additionally, the guideline covers the challenges and strategies for managing upper airway involvement, comorbidities, and exacerbations, as well as socio-medical aspects and disability rights. The importance of patient education and self-management is also emphasized. Finally, the guideline addresses special life stages such as transition, family planning, pregnancy and parenthood, and palliative care. The aim is to ensure comprehensive, consensus-based, and patient-centered care, taking into account individual risks and needs.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":"78 11","pages":"833-899"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Valsalva and Müller maneuvers: who is who and what is what?] [瓦尔萨尔瓦和缪勒手法:谁是谁,什么是什么?]
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-11-01 Epub Date: 2024-07-12 DOI: 10.1055/a-2349-1034
Ulrich Koehler, Mikail Aykut Degerli, Olaf Hildebrandt, Wulf Hildebrandt, Heike Korbmacher-Steiner, Peter von Wichert, Thomas Podszus

The original Valsalva manoeuvre (VM) was described in detail by the Italian anatomist, physician and surgeon Antonio Maria Valsalva (1666-1723). The VM consists of a voluntary forced expiratory effort against a closed upper airway. It was used tradionally in otolaryngology for testing the openess of the eustachian tubes and expelling pus/fluid from the middle to the external ear. VM is associated with increased intrathoracic and -abdominal pressure and leads to hemodynamic changes. The use of VM for cardiovascular purposes was first described by Eduard Friedrich Weber, a German physiologist. The Müller manoeuvre (MM) represents the opposite of the VM by forced inspiration against a closed upper airway. Negative intrathoracic and abdominal pressure (ITP) with direct effects on cardiac function and hemodynamics can be generated by the MM. MM has also been used to simulate the hemodynamic effects of negative ITP in obstructive sleep apnea patients. The Müller manoeuvre was first described by the German anatomist and physician Johannes Müller (1801-1858).

最初的瓦尔萨尔瓦动作(VM)由意大利解剖学家、内科医生和外科医生安东尼奥-玛丽亚-瓦尔萨尔瓦(Antonio Maria Valsalva,1666-1723 年)详细描述。VM 包括在上气道关闭的情况下自主用力呼气。传统上,它被用于耳鼻喉科测试咽鼓管是否通畅,以及将脓液/液体从中耳排出到外耳。VM 与胸腔内和腹腔压力增加有关,并导致血液动力学变化。德国生理学家爱德华-弗里德里希-韦伯(Eduard Friedrich Weber)首次将 VM 用于心血管目的。Müller manoeuvre(MM)与 VM 相反,是在关闭上气道的情况下强制吸气。缪勒动作可产生胸腹负压(ITP),直接影响心脏功能和血液动力学。MM还可用于模拟阻塞性睡眠呼吸暂停患者负ITP对血液动力学的影响。德国解剖学家和医生约翰内斯-缪勒(Johannes Müller,1801-1858 年)首次描述了缪勒动作。
{"title":"[Valsalva and Müller maneuvers: who is who and what is what?]","authors":"Ulrich Koehler, Mikail Aykut Degerli, Olaf Hildebrandt, Wulf Hildebrandt, Heike Korbmacher-Steiner, Peter von Wichert, Thomas Podszus","doi":"10.1055/a-2349-1034","DOIUrl":"10.1055/a-2349-1034","url":null,"abstract":"<p><p>The original Valsalva manoeuvre (VM) was described in detail by the Italian anatomist, physician and surgeon Antonio Maria Valsalva (1666-1723). The VM consists of a voluntary forced expiratory effort against a closed upper airway. It was used tradionally in otolaryngology for testing the openess of the eustachian tubes and expelling pus/fluid from the middle to the external ear. VM is associated with increased intrathoracic and -abdominal pressure and leads to hemodynamic changes. The use of VM for cardiovascular purposes was first described by Eduard Friedrich Weber, a German physiologist. The Müller manoeuvre (MM) represents the opposite of the VM by forced inspiration against a closed upper airway. Negative intrathoracic and abdominal pressure (ITP) with direct effects on cardiac function and hemodynamics can be generated by the MM. MM has also been used to simulate the hemodynamic effects of negative ITP in obstructive sleep apnea patients. The Müller manoeuvre was first described by the German anatomist and physician Johannes Müller (1801-1858).</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"929-934"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141601352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bodyplethysmografie und forcierte Spirometrie – Schritt für Schritt. 人体胸透和强制肺活量测定--逐步进行。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-11-01 Epub Date: 2024-11-08 DOI: 10.1055/a-2267-9510
Stefan Karrasch, Rudolf A Jörres
{"title":"Bodyplethysmografie und forcierte Spirometrie – Schritt für Schritt.","authors":"Stefan Karrasch, Rudolf A Jörres","doi":"10.1055/a-2267-9510","DOIUrl":"https://doi.org/10.1055/a-2267-9510","url":null,"abstract":"","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":"78 11","pages":"922-928"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ). 德文版哮喘损害和风险问卷(AIRQ)的验证。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-11-01 Epub Date: 2024-07-11 DOI: 10.1055/a-2346-9840
Frank Kanniess, Kerstin Defosse, Marek Lommatzsch, Thomas Schultz, Hartmut Timmermann, Olaf Schmidt, Stefan Heindl, Hans Jörg Baumann, Roland Buhl, Christian Taube, Fabian Höing, Stephanie Korn

Background: The Asthma Impairment and Risk Questionnaire (AIRQ), a 10-item, equally weighted, yes/no tool assessing symptom impairment and risk of exacerbations in patients with asthma aged ≥12 years, was developed and validated in a US patient population to evaluate varying levels of asthma control. This study aimed to validate the German language version of the AIRQ in patients aged ≥12 years with different levels of asthma control.

Methods: A cross-sectional, observational, multi-centre study comprising a single visit was conducted in multiple specialised asthma centres and general practices in Germany. A total of 300 patients completed the following measures: 1) Patient Sociodemographic and Clinical Questionnaire, 2) AIRQ, 3) Asthma Control Test (ACT), and 4) Asthma Control Questionnaire (ACQ-6). Logistic regression analyses were conducted to assess the AIRQ score cut points with the greatest predictive validity in discriminating between different control levels relative to a standard of ACT plus prior-year exacerbations or ACQ-6 plus prior-year exacerbations.

Results: The German version of the AIRQ demonstrated a robust capability to correctly identify well-controlled versus not well- or very poorly controlled (AUC values of 0.90 or higher) and well- or not well-controlled versus very poorly controlled asthma (AUC values of 0.89 or higher).

Conclusions: The German version of the AIRQ is a suitable tool to identify adults with varying levels of asthma control, which in turn can help to accurately identify patients with uncontrolled asthma in clinical practice.

背景:哮喘损害和风险问卷(AIRQ)是一种评估年龄≥12岁的哮喘患者的症状损害和病情恶化风险的10个项目、权重相同的是/否工具,该问卷是在美国患者群体中开发和验证的,用于评估不同的哮喘控制水平。本研究旨在对不同哮喘控制水平的≥12岁患者进行德语版AIRQ的验证:方法:在德国多个哮喘专科中心和全科诊所开展了一项横断面、观察性、多中心研究,包括一次就诊。共有 300 名患者完成了以下测量:1)患者社会人口学和临床问卷;2)AIRQ;3)哮喘控制测试(ACT);4)哮喘控制问卷(ACQ-6)。我们进行了逻辑回归分析,以评估相对于 ACT 加前一年哮喘加重或 ACQ-6 加前一年哮喘加重的标准,AIRQ 分数切点在区分不同控制水平方面具有最大的预测效力:德文版 AIRQ 具有强大的能力,可正确识别哮喘控制良好与控制不佳或控制极差(AUC 值为 0.90 或更高),以及哮喘控制良好与控制不佳或控制极差(AUC 值为 0.89 或更高):结论:德文版 AIRQ 是一种合适的工具,可用于识别哮喘控制水平不同的成人,从而有助于在临床实践中准确识别哮喘失控患者。
{"title":"Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ).","authors":"Frank Kanniess, Kerstin Defosse, Marek Lommatzsch, Thomas Schultz, Hartmut Timmermann, Olaf Schmidt, Stefan Heindl, Hans Jörg Baumann, Roland Buhl, Christian Taube, Fabian Höing, Stephanie Korn","doi":"10.1055/a-2346-9840","DOIUrl":"10.1055/a-2346-9840","url":null,"abstract":"<p><strong>Background: </strong>The Asthma Impairment and Risk Questionnaire (AIRQ), a 10-item, equally weighted, yes/no tool assessing symptom impairment and risk of exacerbations in patients with asthma aged ≥12 years, was developed and validated in a US patient population to evaluate varying levels of asthma control. This study aimed to validate the German language version of the AIRQ in patients aged ≥12 years with different levels of asthma control.</p><p><strong>Methods: </strong>A cross-sectional, observational, multi-centre study comprising a single visit was conducted in multiple specialised asthma centres and general practices in Germany. A total of 300 patients completed the following measures: 1) Patient Sociodemographic and Clinical Questionnaire, 2) AIRQ, 3) Asthma Control Test (ACT), and 4) Asthma Control Questionnaire (ACQ-6). Logistic regression analyses were conducted to assess the AIRQ score cut points with the greatest predictive validity in discriminating between different control levels relative to a standard of ACT plus prior-year exacerbations or ACQ-6 plus prior-year exacerbations.</p><p><strong>Results: </strong>The German version of the AIRQ demonstrated a robust capability to correctly identify well-controlled versus not well- or very poorly controlled (AUC values of 0.90 or higher) and well- or not well-controlled versus very poorly controlled asthma (AUC values of 0.89 or higher).</p><p><strong>Conclusions: </strong>The German version of the AIRQ is a suitable tool to identify adults with varying levels of asthma control, which in turn can help to accurately identify patients with uncontrolled asthma in clinical practice.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"912-921"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11548954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ist die VATS tatsächlich der Goldstandard in der Diagnostik des malignen Mesothelioms? VATS 真的是诊断恶性间皮瘤的金标准吗?
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-11-01 Epub Date: 2024-11-08 DOI: 10.1055/a-2325-6578
Hermann Tonn
{"title":"Ist die VATS tatsächlich der Goldstandard in der Diagnostik des malignen Mesothelioms?","authors":"Hermann Tonn","doi":"10.1055/a-2325-6578","DOIUrl":"https://doi.org/10.1055/a-2325-6578","url":null,"abstract":"","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":"78 11","pages":"829"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparison of hospitalized patients with SARS-CoV-2 infection in two time periods of the pandemic]. [两个时期感染 SARS-CoV-2 的住院病人的比较]。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-10-01 Epub Date: 2024-02-20 DOI: 10.1055/a-2235-0214
Jan Eberhard Strehl, Santiago Ewig, Bernhard Schaaf

Objective: The aim of the investigation was to compare patients hospitalized with SARS-CoV-2 infection during 2020/2021 and 2022 with respect to the reason for hospitalization as well as severity of disease at admission, during follow-up and clinical outcomes.

Methods: The data of all patients patients hospitalized with SARS-CoV-2 infection during the periods of interest were collected. Severity of disease at admission and during follow-up was compared in all patients who were hospitalized because of SARS-CoV-2 infection.

Results: During the period of 2020 to 2021, overall n=1281 patients with SARS-CoV-2 infection were hospitalized as compared to n=580 in 2022. Of these, 90% and 42%, respectively, were admitted because of SARS-CoV-2 infection. The rates of nosocomial transmission increased from 5 to 18%. Severity of disease at admission and during follow-up was higher across all age groups in the first period. More patients were admitted to the ICU (25 versus 4%). Accordingly, hospital mortality was higher (17 versus 10%). Intubated patients had a high mortality of 74 and 80%, respectively, in both periods.

Conclusions: The severity at admission and during follow-up was much higher in the first period. In the second period, the burden of health care systems was only in part driven by disease severity but more by the need for isolation and nosocomial infections. Mortality of intubated patients was high.

调查目的调查旨在比较 2020/2021 年和 2022 年期间因感染 SARS-CoV-2 而住院的患者的住院原因、入院时的病情严重程度、随访期间和临床结果:方法:收集了相关时期内所有感染SARS-CoV-2住院患者的数据。比较了所有因感染 SARS-CoV-2 而住院的患者入院时和随访期间的病情严重程度:结果:在 2020 年至 2021 年期间,共有约 1281 名 SARS-CoV-2 感染者住院治疗,而 2022 年则有约 580 名。其中,分别有 90% 和 42% 的患者因感染 SARS-CoV-2 而入院。院内传播率从 5% 上升到 18%。在第一阶段,所有年龄组的患者在入院时和随访期间的病情严重程度都较高。更多患者住进了重症监护室(25% 对 4%)。因此,住院死亡率也更高(17% 对 10%)。在这两个时期,插管患者的死亡率分别为 74% 和 80%:结论:入院时和随访期间的严重程度在第一阶段要高得多。结论:入院时和随访期间的病情严重程度在第一阶段要高得多,而在第二阶段,医疗系统的负担部分是由病情严重程度造成的,但更多的是由隔离需求和院内感染造成的。插管病人的死亡率很高。
{"title":"[Comparison of hospitalized patients with SARS-CoV-2 infection in two time periods of the pandemic].","authors":"Jan Eberhard Strehl, Santiago Ewig, Bernhard Schaaf","doi":"10.1055/a-2235-0214","DOIUrl":"10.1055/a-2235-0214","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the investigation was to compare patients hospitalized with SARS-CoV-2 infection during 2020/2021 and 2022 with respect to the reason for hospitalization as well as severity of disease at admission, during follow-up and clinical outcomes.</p><p><strong>Methods: </strong>The data of all patients patients hospitalized with SARS-CoV-2 infection during the periods of interest were collected. Severity of disease at admission and during follow-up was compared in all patients who were hospitalized because of SARS-CoV-2 infection.</p><p><strong>Results: </strong>During the period of 2020 to 2021, overall n=1281 patients with SARS-CoV-2 infection were hospitalized as compared to n=580 in 2022. Of these, 90% and 42%, respectively, were admitted because of SARS-CoV-2 infection. The rates of nosocomial transmission increased from 5 to 18%. Severity of disease at admission and during follow-up was higher across all age groups in the first period. More patients were admitted to the ICU (25 versus 4%). Accordingly, hospital mortality was higher (17 versus 10%). Intubated patients had a high mortality of 74 and 80%, respectively, in both periods.</p><p><strong>Conclusions: </strong>The severity at admission and during follow-up was much higher in the first period. In the second period, the burden of health care systems was only in part driven by disease severity but more by the need for isolation and nosocomial infections. Mortality of intubated patients was high.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"785-792"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[DGP Congress 2024 - Key takeaways of keynote lectures: Pneumonology, future- and prevention-oriented, is blossoming]. [2024 年 DGP 大会 - 主题演讲的主要收获:面向未来和预防的肺炎学正在蓬勃发展]。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-10-01 Epub Date: 2024-08-05 DOI: 10.1055/a-2370-1868
Michael Kreuter, Wolfram Windisch, Hubert Schädler
{"title":"[DGP Congress 2024 - Key takeaways of keynote lectures: Pneumonology, future- and prevention-oriented, is blossoming].","authors":"Michael Kreuter, Wolfram Windisch, Hubert Schädler","doi":"10.1055/a-2370-1868","DOIUrl":"10.1055/a-2370-1868","url":null,"abstract":"","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"689-692"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nicht invasive Beatmung und High-Flow-Therapie: Lebensretter nicht nur bei COPD. 无创通气和高流量疗法:不仅是慢性阻塞性肺病的救星。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-10-01 Epub Date: 2024-10-18 DOI: 10.1055/a-2381-1408
Felix Bronisch, Thomas Gude, F Joachim Meyer
{"title":"Nicht invasive Beatmung und High-Flow-Therapie: Lebensretter nicht nur bei COPD.","authors":"Felix Bronisch, Thomas Gude, F Joachim Meyer","doi":"10.1055/a-2381-1408","DOIUrl":"https://doi.org/10.1055/a-2381-1408","url":null,"abstract":"","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":"78 10","pages":"793-810"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Implementation of smoking cessation in the workflow of a lung cancer screening program in Germany - A Position Paper of the German Respiratory Society (DGP)]. [德国肺癌筛查项目工作流程中的戒烟实施--德国呼吸学会(DGP)立场文件]。
IF 1.7 Q4 RESPIRATORY SYSTEM Pub Date : 2024-09-01 Epub Date: 2024-07-17 DOI: 10.1055/a-2363-5780
Alexander Rupp, Sebastian Sohrab, Wulf Pankow, Matthias Raspe, Daniel Kotz, Christa Rustler, Torsten Gerriet Blum, Torsten Bauer, Wolfram Windisch, Stefan Andreas

Both tobacco cessation and low-dose CT screening in at-risk individuals reduce lung cancer-specific and all-cause mortality. As part of a national screening program for the early detection of lung cancer, smoking cessation must be a mandatory part of the counseling given to participants. This increases the cost-benefit effectiveness of the screening program. As part of the initial consultation evidence-based measures for smoking cessation must be offered to smoking participants of the screening program in form of a minimal intervention. If participants do not want to participate in a quit smoking measure they must actively refuse (opt-out rule). The costs of quitting smoking, including the costs of withdrawal-inhibiting medication, have to be fully covered by statutory health insurance for participants in the lung cancer screening program.

对高危人群进行戒烟和低剂量 CT 筛查可降低肺癌特异性死亡率和全因死亡率。作为全国性肺癌早期筛查项目的一部分,戒烟必须成为向参与者提供咨询的强制性内容。这将提高筛查计划的成本效益。作为初步咨询的一部分,必须以最低限度干预的形式向参加筛查计划的吸烟者提供以证据为基础的戒烟措施。如果参与者不想参加戒烟措施,他们必须主动拒绝(选择退出规则)。戒烟费用,包括戒断抑制药物的费用,必须由法定医疗保险全额支付给肺癌筛查项目的参与者。
{"title":"[Implementation of smoking cessation in the workflow of a lung cancer screening program in Germany - A Position Paper of the German Respiratory Society (DGP)].","authors":"Alexander Rupp, Sebastian Sohrab, Wulf Pankow, Matthias Raspe, Daniel Kotz, Christa Rustler, Torsten Gerriet Blum, Torsten Bauer, Wolfram Windisch, Stefan Andreas","doi":"10.1055/a-2363-5780","DOIUrl":"10.1055/a-2363-5780","url":null,"abstract":"<p><p>Both tobacco cessation and low-dose CT screening in at-risk individuals reduce lung cancer-specific and all-cause mortality. As part of a national screening program for the early detection of lung cancer, smoking cessation must be a mandatory part of the counseling given to participants. This increases the cost-benefit effectiveness of the screening program. As part of the initial consultation evidence-based measures for smoking cessation must be offered to smoking participants of the screening program in form of a minimal intervention. If participants do not want to participate in a quit smoking measure they must actively refuse (opt-out rule). The costs of quitting smoking, including the costs of withdrawal-inhibiting medication, have to be fully covered by statutory health insurance for participants in the lung cancer screening program.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"612-619"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of nocturnal ventilation by pulmonary function testing in patients with amyotrophic lateral sclerosis. 通过肺功能测试预测肌萎缩侧索硬化症患者的夜间通气量。
IF 1.2 Q4 RESPIRATORY SYSTEM Pub Date : 2024-09-01 Epub Date: 2024-07-30 DOI: 10.1055/a-2349-0936
Friederike Tress, Eva Luecke, Sabine Stegemann-Koniszewski, Anke Lux, Abhinav Singla, Jens Schreiber

Background: In amyotrophic lateral sclerosis (ALS) prognosis is poor due to progressive weakening of the respiratory muscles. Survival and quality of life can be improved by noninvasive ventilation (NIV), which is initially applied while sleeping. The indication for NIV is based on pulmonary function testing (PFT) and polysomnography (PSG) with capnography (tCO2). While it is desirable to predict nocturnal ventilation by waking PFT in ALS, the parameters suited for reliable predictions remain elusive.

Methods: We retrospectively analyzed parameters derived from PFT (spirometry, body plethysmography, diffusion capacity, respiratory muscle testing) and blood gas analysis, PSG and tCO2 in 42 patients with ALS (27 men, 15 women, age 69 ± 12.1 years) and performed Spearman's correlation analysis of daytime waking parameters and nighttime sleep parameters.

Results: 28 patients (66.7%) showed restrictive impairment of ventilation and 15 patients (48.3%) showed insufficiency of the respiratory musculature. There was no obstructive impairment of ventilation. We did not observe any significant correlations between any single daytime PFT parameter with nocturnal pCO2. However, there were significant correlations between the ratios PIF/PEF, MEF50/MIF50, DLCO/VA as well as FEV1/FVC and nocturnal pCO2. Highly normal FEV1/FVC and Krogh-Factor (DLCOc/VA) indicated nocturnal hypercapnia. Furthermore, waking hypercapnia, concentrations of bicarbonate and base excess were each positively correlated with nocturnal hypercapnia.

Conclusions: Waking PFT is not a good predictor of nocturnal ventilation. Inspiratory parameters as well as the ratios FEV1/FVC and DLCO/VA performed best and should be included in the interpretation. Our analyses confirm the relevance of inspiratory muscle weakness in ALS. PSG and tCO2 remain the gold standard for the assessment of nocturnal ventilation.

背景:肌萎缩性脊髓侧索硬化症(ALS)由于呼吸肌逐渐衰弱,预后很差。无创通气(NIV)可以提高患者的生存率和生活质量。无创通气的适应症是基于肺功能测试(PFT)和多导睡眠图(PSG)以及二氧化碳饱和度(tCO2)。虽然通过 ALS 清醒时的 PFT 预测夜间通气情况是可取的,但适合进行可靠预测的参数仍然难以确定:我们回顾性分析了 42 名 ALS 患者(27 名男性,15 名女性,年龄 69 ± 12.1 岁)的 PFT(肺活量测定、体液描记术、弥散容量、呼吸肌测试)和血气分析、PSG 和 tCO2 得出的参数,并对白天清醒参数和夜间睡眠参数进行了斯皮尔曼相关性分析。没有出现阻塞性通气障碍。我们没有观察到任何单一的日间 PFT 参数与夜间 pCO2 之间存在明显的相关性。但是,PIF/PEF、MEF50/MIF50、DLCO/VA 和 FEV1/FVC 与夜间 pCO2 之间存在明显的相关性。FEV1/FVC 和 Krogh 因子(DLCOc/VA)高度正常表明存在夜间高碳酸血症。此外,清醒时高碳酸血症、碳酸氢盐浓度和碱过量均与夜间高碳酸血症呈正相关:结论:清醒时的肺活量不能很好地预测夜间通气。吸气参数以及 FEV1/FVC 和 DLCO/VA 的比率表现最佳,应纳入解释中。我们的分析证实了 ALS 患者吸气肌无力的相关性。PSG 和 tCO2 仍是评估夜间通气的黄金标准。
{"title":"Prediction of nocturnal ventilation by pulmonary function testing in patients with amyotrophic lateral sclerosis.","authors":"Friederike Tress, Eva Luecke, Sabine Stegemann-Koniszewski, Anke Lux, Abhinav Singla, Jens Schreiber","doi":"10.1055/a-2349-0936","DOIUrl":"10.1055/a-2349-0936","url":null,"abstract":"<p><strong>Background: </strong>In amyotrophic lateral sclerosis (ALS) prognosis is poor due to progressive weakening of the respiratory muscles. Survival and quality of life can be improved by noninvasive ventilation (NIV), which is initially applied while sleeping. The indication for NIV is based on pulmonary function testing (PFT) and polysomnography (PSG) with capnography (tCO<sub>2</sub>). While it is desirable to predict nocturnal ventilation by waking PFT in ALS, the parameters suited for reliable predictions remain elusive.</p><p><strong>Methods: </strong>We retrospectively analyzed parameters derived from PFT (spirometry, body plethysmography, diffusion capacity, respiratory muscle testing) and blood gas analysis, PSG and tCO<sub>2</sub> in 42 patients with ALS (27 men, 15 women, age 69 ± 12.1 years) and performed Spearman's correlation analysis of daytime waking parameters and nighttime sleep parameters.</p><p><strong>Results: </strong>28 patients (66.7%) showed restrictive impairment of ventilation and 15 patients (48.3%) showed insufficiency of the respiratory musculature. There was no obstructive impairment of ventilation. We did not observe any significant correlations between any single daytime PFT parameter with nocturnal pCO<sub>2</sub>. However, there were significant correlations between the ratios PIF/PEF, MEF50/MIF50, DLCO/VA as well as FEV<sub>1</sub>/FVC and nocturnal pCO<sub>2</sub>. Highly normal FEV<sub>1</sub>/FVC and Krogh-Factor (DLCOc/VA) indicated nocturnal hypercapnia. Furthermore, waking hypercapnia, concentrations of bicarbonate and base excess were each positively correlated with nocturnal hypercapnia.</p><p><strong>Conclusions: </strong>Waking PFT is not a good predictor of nocturnal ventilation. Inspiratory parameters as well as the ratios FEV<sub>1</sub>/FVC and DLCO/VA performed best and should be included in the interpretation. Our analyses confirm the relevance of inspiratory muscle weakness in ALS. PSG and tCO<sub>2</sub> remain the gold standard for the assessment of nocturnal ventilation.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"626-633"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pneumologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1